A detailed history of Financial Gravity Asset Management, Inc. transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Financial Gravity Asset Management, Inc. holds 1 shares of BGNE stock, worth $147. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1
Holding current value
$147
% of portfolio
0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$141.8 - $181.47 $141 - $181
1 New
1 $223,000
Q2 2023

Aug 08, 2023

BUY
$178.3 - $266.78 $31,737 - $47,486
178 New
178 $184,000
Q4 2022

Feb 15, 2023

BUY
$125.51 - $229.3 $27,612 - $50,446
220 New
220 $227,000

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $15.3B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Financial Gravity Asset Management, Inc. Portfolio

Follow Financial Gravity Asset Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Financial Gravity Asset Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Financial Gravity Asset Management, Inc. with notifications on news.